The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Press release from Marketwire

Paladin Labs Completes Acquisition of Labopharm

Friday, October 07, 2011

Paladin Labs Completes Acquisition of Labopharm15:38 EDT Friday, October 07, 2011MONTREAL, CANADA--(Marketwire - Oct. 7, 2011) - Paladin Labs Inc. (TSX:PLB), a leading Canadian specialty pharmaceutical company, today announced that it has completed its previously announced acquisition of all of the outstanding common shares of Labopharm Inc. For full details of this transaction, refer to the August 17, 2011 press release."The acquisition of Labopharm will add to our top line, through the addition of established international revenue streams, and will provide us the opportunity to build upon our existing operational capabilities. Moreover, Labopharm's worldwide partnerships provide us with an exciting opportunity to continue cultivating important relationships internationally," stated Mark Beaudet, interim President & CEO of Paladin Labs Inc.About Paladin Labs Inc. Paladin Labs Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian and world markets. With this strategy, a focused national sales team and proven marketing expertise, Paladin has evolved into one of Canada's leading specialty pharmaceutical companies. Paladin's shares trade on the Toronto Stock Exchange under the symbol PLB. For more information about Paladin, please visit the Company's web site at www.paladinlabs.com.This press release may contain forward-looking statements and predictions. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. The Company considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared, but cautions that these assumptions regarding the future events, many of which are beyond the control of the Company and its subsidiaries, may ultimately prove to be incorrect. Factors and risks, which could cause actual results to differ materially from current expectations, are discussed in the annual report as well as in the Company's Annual Information Form for the year ended December 31, 2010. The Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information or future event, except as required by law. For additional information on risks and uncertainties relating to these forward-looking statements, investors should consult the Company's ongoing quarterly fillings, annual report and Annual Information Form and other fillings found on SEDAR at www.sedar.com.FOR FURTHER INFORMATION PLEASE CONTACT: Chief Financial OfficerSamira Sakhia, CA, MBAPaladin Labs Inc.Tel: 514-669-5367514-344-4675 (FAX)Email: info@paladinlabs.comWebsite: www.paladinlabs.com